How to Get Tresiba in West Virginia

What Is Tresiba and Why Do West Virginia Patients Request It?

Tresiba is a long-acting basal insulin with an ultra-long duration of action exceeding 42 hours, giving it a flatter, more stable pharmacokinetic profile than insulin glargine U-100 or insulin detemir. West Virginia has the fourth-highest age-adjusted rate of diagnosed diabetes in the United States at 14.5%, according to CDC surveillance data, which means demand for effective basal insulins is high across the state. [1]

The FDA approved insulin degludec in September 2015 for adults with type 1 or type 2 diabetes, and a subsequent label update extended the indication to children aged 1 year and older. [2] The approval was supported by the BEGIN trial program, a series of phase 3 randomized controlled trials that collectively enrolled more than 14,000 participants. Across the BEGIN trials, insulin degludec achieved HbA1c reductions comparable to insulin glargine with a statistically significant lower rate of nocturnal confirmed hypoglycemia. In BEGIN Basal-Bolus Type 1 (N=629), nocturnal hypoglycemia occurred at a rate of 3.91 episodes per patient-year with degludec versus 5.22 per patient-year with glargine U-100, a relative reduction of 25% (P<0.001). [3]

The DEVOTE cardiovascular outcomes trial (N=7,637, median follow-up 2.0 years) published in the New England Journal of Medicine in 2017 found that insulin degludec was non-inferior to insulin glargine U-100 for major adverse cardiovascular events (MACE) in patients with type 2 diabetes at high cardiovascular risk, with a hazard ratio of 0.91 (95% CI 0.78 to 1.06). [4] DEVOTE also recorded a 40% lower rate of severe hypoglycemia with degludec compared with glargine (rate ratio 0.60 to 95% CI 0.48 to 0.76, P<0.001). [4]

These outcomes matter for West Virginia prescribers because West Virginia's cardiovascular disease mortality rate ranks among the highest in the nation, making hypoglycemia-associated cardiac risk a relevant clinical concern. [5]

Who Can Prescribe Tresiba in West Virginia?

Any licensed prescriber with authority to write for controlled and non-controlled prescription drugs can prescribe insulin degludec in West Virginia. That group includes physicians (MD, DO), nurse practitioners (APRN-CNP), and physician assistants (PA-C). [6]

West Virginia was one of the earlier states to grant full practice authority to APRNs in rural areas, a move codified under WV Code §30-7-15a. Nurse practitioners in West Virginia may prescribe insulin degludec without a collaborative agreement once they have completed 3 years or 3 to 600 hours of supervised practice. PAs prescribe under a supervision agreement with a collaborating physician, though that agreement does not restrict the drug formulary and does not prevent insulin prescribing. [6]

For patients in rural counties such as McDowell, Mingo, or Webster, finding an in-person endocrinologist may require driving more than 90 minutes. The West Virginia University Diabetes Care Center in Morgantown and Marshall University Joan C. Edwards School of Medicine clinics in Huntington are the two main academic endocrinology centers. Primary care physicians and APRNs, however, write the majority of insulin prescriptions in the state.

Telehealth Prescribing for Tresiba in West Virginia

Telehealth providers can legally prescribe Tresiba to West Virginia patients. West Virginia enacted a telehealth parity law under WV Code §33-15-4r requiring commercial insurers to reimburse telehealth visits at parity with in-person visits, and the state's medical practice act permits prescribing following a synchronous audio-visual evaluation. [7]

Federal DEA regulations do not restrict non-controlled insulin prescribing via telehealth, so no in-person visit is legally required before a provider issues an insulin degludec prescription. A licensed telehealth platform can conduct a complete intake visit, review uploaded lab results, and send a prescription electronically to any West Virginia-licensed pharmacy within the same session. Typical telehealth visit turnaround from booking to prescription is 24 to 72 hours on most platforms.

The prescriber must hold an active West Virginia medical license or APRN license. Patients should confirm this before scheduling. Telehealth platforms that operate nationwide are not automatically licensed in every state; checking the prescriber's WV license number on the West Virginia Board of Medicine online verification portal takes about two minutes and prevents delays. [8]

HealthRX Telehealth-to-Pharmacy Pathway for West Virginia Tresiba Patients

1. Book a synchronous video or phone visit with a WV-licensed prescriber.
2. Upload recent labs (HbA1c, fasting glucose, CMP) taken within the past 90 days, or request a lab order at intake.
3. Prescriber reviews history, confirms diagnosis, and writes an electronic prescription.
4. Prescription routes to your preferred WV retail, mail-order, or specialty pharmacy.
5. If commercial insurance requires prior authorization, prescriber's office submits PA documentation simultaneously.
6. Expect first fill within 2 to 5 business days if PA is not required; 7 to 14 days if PA is pending.

What Labs Are Required Before Starting Tresiba?

Baseline labs are not a legal prerequisite to dispensing insulin degludec, but every responsible prescriber will want to document a diagnostic workup before initiating any basal insulin. The American Diabetes Association 2024 Standards of Care specify HbA1c measurement at least twice per year in patients with stable glycemic control and quarterly when therapy is being adjusted. [9]

Before a provider prescribes Tresiba for a new patient, expect the following panel:

• HbA1c: Confirms diagnosis and establishes a baseline for titration targets. An HbA1c of 7.0% or below is the general ADA target for most non-pregnant adults. [9]
• Fasting plasma glucose: Guides starting dose selection; the package insert recommends beginning at 10 units once daily for insulin-naive type 2 patients. [2]
• Comprehensive metabolic panel (CMP): Evaluates hepatic and renal function. Insulin degludec does not require dose adjustment for renal impairment per the FDA label, but renal decline affects overall insulin sensitivity and hypoglycemia risk. [2]
• C-peptide and fasting insulin (type 1 evaluation): Needed to distinguish type 1 from latent autoimmune diabetes in adults (LADA) when the diagnosis is uncertain.
• Thyroid-stimulating hormone (TSH): Often checked at baseline because thyroid dysfunction alters insulin requirements in both directions.

Labs drawn within 90 days of the telehealth visit are generally accepted. Results older than 6 months typically require a repeat draw before the prescriber will initiate therapy.

West Virginia Pharmacies and Tresiba Dispensing

Tresiba is commercially available as a 100 units/mL FlexTouch pen (3 mL, 5-pack) and a 200 units/mL FlexTouch pen (3 mL, 5-pack). Both concentrations are stocked at major retail chains in West Virginia, including CVS, Walgreens, Kroger Pharmacy, and Walmart Pharmacy. Small independent pharmacies in rural counties may require 24 to 48 hours to special-order the 200 units/mL concentration.

Mail-order options such as CVS Caremark, Express Scripts, and OptumRx ship to West Virginia addresses and typically offer 90-day supplies at lower per-unit cost under commercial insurance plans. Patients using mail-order for insulin should confirm cold-chain shipping protocols, particularly during West Virginia's summer months when package temperatures can exceed safe ranges.

503A compounding pharmacies licensed in West Virginia may compound insulin products for patient-specific prescriptions, provided the compound meets USP 797 sterile compounding standards. [10] Compounded insulin degludec is not bioequivalent to the FDA-approved Tresiba product and does not carry the same safety and efficacy data. The FDA has issued guidance clarifying that compounded insulin products are not substitutes for FDA-approved insulins. [11] Patients considering a compounded insulin for cost reasons should discuss risks explicitly with their prescriber.

Cash price for a 5-pack of Tresiba 100 units/mL FlexTouch pens at major West Virginia pharmacies ranges from approximately $380 to $430 per month without insurance or assistance programs as of 2025.

West Virginia Medicaid and Insurance Coverage

West Virginia Medicaid does not include Tresiba on its preferred drug list as of 2025. Medicaid-enrolled patients needing a long-acting basal insulin are typically directed to insulin glargine biosimilars (Semglee, Rezvoglar) or insulin detemir, which appear on the WV Medicaid preferred drug list. [12] A non-preferred exception request can be submitted, but approval rates are low without documented failure of preferred agents.

Commercial insurance plans operating in West Virginia vary widely. Most BlueCross BlueShield of WV, United Healthcare, and Aetna formularies place Tresiba on Tier 3 or Tier 4, requiring prior authorization. Prior authorization for Tresiba under commercial plans in West Virginia typically requires:

1. Documentation of a confirmed type 1 or type 2 diabetes diagnosis (ICD-10 E10.x or E11.x).
2. Evidence of trial and inadequate response or intolerance to at least one preferred basal insulin (insulin glargine or detemir).
3. A prescriber attestation that degludec is medically necessary, often citing hypoglycemia risk or dosing-flexibility requirements.
4. Recent HbA1c and fasting glucose values.

The ADA's position statement on insulin access notes that "insurance coverage restrictions and high cost-sharing remain the primary barriers to optimal insulin therapy for Americans with diabetes." [9] PA approval timelines in West Virginia run 5 to 15 business days under state insurance regulations that require commercial insurers to resolve standard PA requests within 72 hours for urgent cases and 15 calendar days for non-urgent cases. [13]

Novo Nordisk Patient Assistance and the My$99Insulin Program

Novo Nordisk offers insulin degludec at $99 per month (up to three packs of FlexTouch pens) through its My$99Insulin program for patients who are uninsured, underinsured, or unable to afford their copay. [14] Eligibility requires:

• A valid US prescription.
• Income at or below 400% of the federal poverty level, OR documented insurance coverage that still leaves insulin unaffordable.
• Residency in the United States, including West Virginia.

Enrollment takes approximately 15 minutes online. Approved patients receive a savings card usable at participating retail pharmacies. The program does not require WV Medicaid enrollment status verification, making it accessible to cash-pay patients regardless of insurance type.

The NeedyMeds database lists additional pharmaceutical assistance programs for West Virginia residents, and the West Virginia Department of Health operates a Diabetes Prevention and Control Program that can connect patients with local resources. [15]

Transferring an Existing Tresiba Prescription to West Virginia

A prescription for Tresiba written in another state can be transferred to a West Virginia pharmacy under federal and state pharmacy law, provided the original prescription has remaining refills and was issued by a licensed prescriber. [16] Non-controlled drug prescriptions, including all insulins, are transferable between states.

The practical steps are:

1. Ask the receiving West Virginia pharmacy to contact the original dispensing pharmacy and request a transfer.
2. Confirm the prescriber on the original Rx holds an active license. If the prescriber is not licensed in WV, the WV pharmacy can still fill the remaining refills on the transferred script under federal law, but cannot call in new refills from that prescriber.
3. If the original prescription is exhausted, schedule a telehealth visit with a WV-licensed provider to issue a new prescription.

Mail-order pharmacies enrolled in a national pharmacy benefit manager network can continue filling prescriptions from out-of-state prescribers as long as the prescriber holds a DEA registration and the drug is non-controlled. For insulin degludec, DEA registration is not required, so only state licensure matters.

Titrating Tresiba After Your First Fill

The Tresiba package insert recommends a starting dose of 10 units once daily for insulin-naive type 2 patients, with titration upward in increments of 2 units every 3 to 4 days until fasting plasma glucose reaches 80 to 90 mg/dL. [2] For patients converting from another basal insulin, the FDA label specifies unit-for-unit conversion from insulin glargine U-100 or insulin detemir, with a possible 20% dose reduction when switching from high-dose detemir to reduce hypoglycemia risk. [2]

The American Association of Clinical Endocrinology (AACE) 2022 Diabetes Algorithm recommends basal insulin titration guided by self-monitored fasting glucose targets, with a treat-to-target approach rather than a fixed-dose protocol. [17] West Virginia patients using continuous glucose monitoring (CGM) devices, which are covered under most commercial plans and Medicare Part B for insulin-using patients, can track time-in-range as a secondary titration endpoint. [9]

Tresiba's flexible dosing window, which the FDA label describes as a minimum 8-hour interval between doses, is a practical advantage for shift workers and patients with irregular schedules, a population that is disproportionately represented in West Virginia's manufacturing and coal sectors. [2]

Hypoglycemia Risk and Safety Monitoring in WV Patients

Severe hypoglycemia is the most common serious adverse event with basal insulin therapy. In DEVOTE (N=7,637), the rate of severe hypoglycemia was 1.48 episodes per 100 patient-years with insulin degludec versus 2.46 per 100 patient-years with insulin glargine U-100, a 40% reduction (rate ratio 0.60 to 95% CI 0.48 to 0.76, P<0.001). [4] This difference is clinically meaningful for West Virginia patients with limited access to emergency services in rural counties.

Prescribers should counsel all patients on hypoglycemia recognition and treatment, including the 15-15 rule (15 grams of fast-acting carbohydrate, recheck glucose in 15 minutes). Glucagon emergency kits (nasal glucagon Baqsimi or injectable glucagon) should be co-prescribed for patients with type 1 diabetes or type 2 patients with a history of severe hypoglycemia. West Virginia Medicaid does cover glucagon emergency kits on its preferred drug list. [12]

Ongoing monitoring after initiation should include HbA1c at 3-month intervals until stable, fasting glucose logs or CGM data reviewed at each visit, and annual CMP and lipid panel per ADA Standards of Care. [9]

Getting Started: Practical Steps for West Virginia Patients

1. Confirm your diagnosis documentation (type 1 or type 2 ICD-10 code) is on file with a provider.
2. Check whether your commercial insurer requires PA by calling the member services number on your insurance card or reviewing your plan's formulary at healthcare.gov.
3. Book a telehealth visit with a WV-licensed prescriber if no in-person provider is available within a reasonable distance.
4. Submit labs (HbA1c, CMP, fasting glucose) within 90 days before or at your appointment.
5. Ask the prescriber to submit PA documentation simultaneously with the prescription if your insurer requires it.
6. If cost is a barrier, apply to Novo Nordisk's My$99Insulin program before your first fill.
7. Choose a pharmacy with cold-chain mail-order capability if you live in a rural county more than 30 minutes from a retail location.

West Virginia patients with commercial insurance who document prior failure of a preferred basal insulin will receive PA approval for Tresiba in the majority of cases. Starting that PA process on the same day as the prescription reduces total time-to-first-dose to under two weeks in most scenarios.